Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Protalix
Biotech
Protalix eyes 2nd try at Fabry med in 2H22
Protalix intends to resubmit its once-rejected Fabry disease drug to the FDA in the second half of this year thanks to new phase 3 data.
Kyle LaHucik
Mar 18, 2022 9:22am
Protalix sees a path for Fabry resubmission down the line
Oct 11, 2021 10:35am
Protalix, Chiesi edge close to potential Fabry disease approval
May 28, 2020 8:05am
Chiesi creates Boston rare disease unit ahead of Fabry launch
Feb 7, 2020 8:45am
Protalix’ oral anti-TNF drug hits the mark in phase 2
Mar 13, 2018 9:44am
Protalix claims early success with oral anti-TNF candidate
Jan 2, 2018 8:37am
